Page last updated: 2024-12-07

butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine: formyl peptide antagonist and lipoxin A4 receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID125628
CHEMBL ID3311030
SCHEMBL ID6897460
MeSH IDM0103573

Synonyms (22)

Synonym
bplplp
n-t-boc-phe-leu-phe-leu-phe
(2s)-2-[[(2r)-4-methyl-2-[[(2s)-2-[[(2r)-4-methyl-2-[[(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]amino]-3-phenylpropanoic acid
66556-73-8
SCHEMBL6897460
l-phenylalanine, n-(n-(n-(n-(n-((1,1-dimethylethoxy)carbonyl)-l-phenylalanyl)-d-leucyl)-l-phenylalanyl)-d-leucyl)-
n-t-boc-phe-dleu-phe-dleu-phe
butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine
n-tertiary-butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine
butyloxycarbonyl-phe-leu-phe-leu-phe
boc2 cpd
CHEMBL3311030 ,
DTXSID30216738
bdbm50051608
{boc}-phe-leu-phe-leu-phe
HY-P2355
CS-0132590
l-phenylalanine,n-[(1,1-dimethylethoxy)carbonyl]-l-phenylalanyl-d-leucyl-l-phenylalanyl-d-leucyl-
boc-phe-d-leu-phe-d-leu-phe
(6s,9r,12s,15r,18s)-6,12,18-tribenzyl-9,15-diisobutyl-2,2-dimethyl-4,7,10,13,16-pentaoxo-3-oxa-5,8,11,14,17-pentaazanonadecan-19-oic acid
MS-31438
AKOS040758271
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
fMet-Leu-Phe receptorHomo sapiens (human)IC50 (µMol)2.00000.02004.006710.0000AID1184058
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
fMet-Leu-Phe receptorHomo sapiens (human)Kd0.23000.00300.11650.2300AID1184057
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
phospholipase C-activating G protein-coupled receptor signaling pathwayfMet-Leu-Phe receptorHomo sapiens (human)
chemotaxisfMet-Leu-Phe receptorHomo sapiens (human)
signal transductionfMet-Leu-Phe receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayfMet-Leu-Phe receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayfMet-Leu-Phe receptorHomo sapiens (human)
nitric oxide mediated signal transductionfMet-Leu-Phe receptorHomo sapiens (human)
complement receptor mediated signaling pathwayfMet-Leu-Phe receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationfMet-Leu-Phe receptorHomo sapiens (human)
inflammatory responsefMet-Leu-Phe receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayfMet-Leu-Phe receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
G protein-coupled receptor bindingfMet-Leu-Phe receptorHomo sapiens (human)
G protein-coupled receptor activityfMet-Leu-Phe receptorHomo sapiens (human)
N-formyl peptide receptor activityfMet-Leu-Phe receptorHomo sapiens (human)
scavenger receptor bindingfMet-Leu-Phe receptorHomo sapiens (human)
protein bindingfMet-Leu-Phe receptorHomo sapiens (human)
RAGE receptor bindingfMet-Leu-Phe receptorHomo sapiens (human)
complement receptor activityfMet-Leu-Phe receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytoplasmfMet-Leu-Phe receptorHomo sapiens (human)
plasma membranefMet-Leu-Phe receptorHomo sapiens (human)
membranefMet-Leu-Phe receptorHomo sapiens (human)
secretory granule membranefMet-Leu-Phe receptorHomo sapiens (human)
azurophil granule membranefMet-Leu-Phe receptorHomo sapiens (human)
ficolin-1-rich granule membranefMet-Leu-Phe receptorHomo sapiens (human)
plasma membranefMet-Leu-Phe receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1184058Antagonist activity at formyl peptide receptor in human HL60 cells assessed as inhibition of fMLP-induced calcium mobilization incubated for 5 mins prior to fMLP challenge by Fura-2 method2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Development of potent antagonists for formyl peptide receptor 1 based on Boc-Phe-D-Leu-Phe-D-Leu-Phe-OH.
AID1184061Agonist activity at formyl peptide receptor in human HL60 cells at 10 uM by Fura-2 method2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Development of potent antagonists for formyl peptide receptor 1 based on Boc-Phe-D-Leu-Phe-D-Leu-Phe-OH.
AID1184060Antagonist activity at formyl peptide receptor in human HL60 cells assessed as fMLP EC50 at 1 uM incubated for 5 mins prior to fMLP challenge by Fura-2 method2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Development of potent antagonists for formyl peptide receptor 1 based on Boc-Phe-D-Leu-Phe-D-Leu-Phe-OH.
AID1184057Antagonist activity at formyl peptide receptor in human HL60 cells assessed as inhibition of intracellular calcium mobilization incubated for 5 mins prior to fMLP challenge by Fura-2 method2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Development of potent antagonists for formyl peptide receptor 1 based on Boc-Phe-D-Leu-Phe-D-Leu-Phe-OH.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (16.67)18.7374
1990's3 (10.00)18.2507
2000's4 (13.33)29.6817
2010's17 (56.67)24.3611
2020's1 (3.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.52 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index5.01 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.23%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (96.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]